U.S. Markets open in 5 hrs 23 mins
  • S&P Futures

    3,845.25
    +11.00 (+0.29%)
     
  • Dow Futures

    30,926.00
    +17.00 (+0.06%)
     
  • Nasdaq Futures

    13,473.00
    +111.50 (+0.83%)
     
  • Russell 2000 Futures

    2,164.00
    0.00 (0.00%)
     
  • Crude Oil

    52.61
    +0.34 (+0.65%)
     
  • Gold

    1,851.70
    -4.50 (-0.24%)
     
  • Silver

    25.61
    +0.05 (+0.21%)
     
  • EUR/USD

    1.2167
    -0.0007 (-0.0608%)
     
  • 10-Yr Bond

    1.0910
    0.0000 (0.00%)
     
  • Vix

    22.27
    +0.95 (+4.46%)
     
  • GBP/USD

    1.3694
    +0.0010 (+0.0698%)
     
  • USD/JPY

    103.7690
    +0.0080 (+0.0077%)
     
  • BTC-USD

    33,517.69
    +70.44 (+0.21%)
     
  • CMC Crypto 200

    679.32
    +2.42 (+0.36%)
     
  • FTSE 100

    6,690.20
    -4.87 (-0.07%)
     
  • Nikkei 225

    28,822.29
    +190.84 (+0.67%)
     

J&J's COVID-19 vaccine should hopefully show over 80% effectiveness - Slaoui

·1 min read

Jan 13 (Reuters) - Johnson & Johnson's COVID-19 vaccine candidate should hopefully show high effectiveness of 80% to 85%, the chief adviser for Operation Warp Speed Moncef Slaoui said on Wednesday.

"My expectation is high efficacy," Slaoui said at a J.P.Morgan healthcare conference, noting that he hoped anything at 80% or above would receive emergency use authorization in the U.S.

The vaccine, not yet authorized for emergency use in the United States, is in late-stage trials as a single dose vaccine, in contrast to rival two-shot vaccines from Pfizer Inc and Moderna Inc.

Operation Warp Speed is the U.S. government's program to develop and distribute COVID-19 vaccines. (Reporting by Manojna Maddipatla in Bengaluru; Editing by Shounak Dasgupta)